These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 3561773)

  • 21. Meige's syndrome: acute and chronic responses to clonazepan and anticholinergics.
    Hípola D; Mateo D; Giménez-Roldán S
    Eur Neurol; 1984; 23(6):474-8. PubMed ID: 6510447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inability to close eyelids as a feature of palpebral dystonia.
    Krack P; Porschke H; de Decker W; Deuschl G
    Mov Disord; 1997 Mar; 12(2):251-2. PubMed ID: 9087989
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia.
    Lu CS; Chen RS; Tsai CH
    J Formos Med Assoc; 1995 Apr; 94(4):189-92. PubMed ID: 7606182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference Statement, November 12-14, 1990.
    Arch Neurol; 1991 Dec; 48(12):1294-8. PubMed ID: 1845036
    [No Abstract]   [Full Text] [Related]  

  • 28. [Meige's syndrome or segmental craniocervical dystonia: terminology, history and contemporary view].
    Zalyalova ZA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):133-136. PubMed ID: 26978507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.
    Sataloff RT; Heman-Ackah YD; Simpson LL; Park JB; Zwislewski A; Sokolow C; Mandel S
    J Voice; 2002 Sep; 16(3):422-4. PubMed ID: 12395995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facial dystonia: clinical features, prognosis and pharmacology in 31 patients.
    Defazio G; Lamberti P; Lepore V; Livrea P; Ferrari E
    Ital J Neurol Sci; 1989 Dec; 10(6):553-60. PubMed ID: 2515166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.
    Mezaki T; Kaji R; Kohara N; Fujii H; Katayama M; Shimizu T; Kimura J; Brin MF
    Neurology; 1995 Mar; 45(3 Pt 1):506-8. PubMed ID: 7898706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
    Park YC; Lim JK; Lee DK; Yi SD
    J Korean Med Sci; 1993 Oct; 8(5):334-40. PubMed ID: 8305141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological study in Meige's syndrome with predominant blepharospasm.
    Ransmayr G; Kleedorfer B; Dierckx RA; Poewe W; Kemmler GW; Gerstenbrand F
    Clin Neuropharmacol; 1988 Feb; 11(1):68-76. PubMed ID: 3280128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholinergic pharmacology of blepharospasm with oromandibular dystonia (Meige's syndrome).
    Klawans HL; Tanner CM
    Adv Neurol; 1988; 49():443-50. PubMed ID: 3278551
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia.
    Müller J; Wenning GK; Wissel J; Seppi K; Poewe W
    J Neurol; 2002 Mar; 249(3):300-4. PubMed ID: 11993530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin in Meige's syndrome: A video-based case series.
    Pandey S; Sharma S
    Neurol India; 2018; 66(1):71-76. PubMed ID: 29322963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin for the treatment of movement disorders.
    Thenganatt MA; Fahn S
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):399-409. PubMed ID: 22661378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of botulinum toxin on ocular tissue.
    Smith H
    Nurs Times; 1995 Jan 25-31; 91(4):41-3. PubMed ID: 7862573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
    Lew MF; Adornato BT; Duane DD; Dykstra DD; Factor SA; Massey JM; Brin MF; Jankovic J; Rodnitzky RL; Singer C; Swenson MR; Tarsy D; Murray JJ; Koller M; Wallace JD
    Neurology; 1997 Sep; 49(3):701-7. PubMed ID: 9305326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.